Intensity Therapeutics, Inc. (INTS) Misses Q2 EPS by 103c
Tweet
Share
E-mailGet Alerts INTS Hot Sheet
Join SI Premium – FREE
Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q2 EPS of ($1.43), $1.03 worse than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Phreesia Inc. (PHR) to Market Perform
- UBS Upgrades Feng Tay Enterprises (9910:TT) to Buy
- Citi upgrades Old Dominion Freight Line to Buy with $223 target
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
